Sleep Quality Analysis in Metastatic Breast Cancer Patients Receiving Cyclin-Dependent Kinase 4-6 Inhibitor
Received Date : 09 May 2022
Accepted Date : 04 Aug 2022
Available Online : 24 Aug 2022
Doi: 10.37047/jos.2022-91240 - Article's Language: EN
J Oncol Sci. 2022;8(3):113-8
This is an open access article under the CC BY-NC-ND license
Objective: Sleep quality(SQ) can be steady decline in the of breast cancer patients after treatment. The aim of this study was to assess the SQ of breast cancer patients treated with Cyclin-dependent kinase(CDK) 4–6 inhibitor plus endocrine therapy(ET). Metarial and Methods: The data were collected from three different cancer centers. Eighty consecutive patients were included in this study. The Pittsburg Sleep Quality Index(PSQI) was employed for the assessment of the SQ in metastatic breast cancer patients after receiving treatment with CDK4–6 inhibitors plus ET for at least three months. Results: The PSQI scores revealed that 68.8% of patients treated with CDK4–6 plus ET have poor SQ. The mean score of the PSQI was 8 (ranging from 1-17). Univariate analysis was employed, revealing a significantly higher sleep latency (p= 0.024), sleep disturbance (p= 0.011), and daytime dysfunction (p= 0.012) in patients receiving letrozole as compared to patients treated with Fulvestrant. Similarly, the mean score of the PSQI was also higher in letrozole-treated patients in comparison with Fulvestrant- treated patients (p= 0.042). The multivariate analysis revealed a significantly higher rate of daytime dysfunction in letrozole-treated patients as compared to Fulvestrant-treated patients (The odds ratio was 0.51, 95% confidence interval, 0.30 to 0.86; p=0.008). In addition, no significant difference was observed in the sleep quality of patients receiving either Ribociclib or Palbociclib. Conclusion: The study evidently shows worsening of SQ in patients receiving letrozole in comparison with patients receiving Fulvestrant. CDK4–6 inhibitors have a similar effect on SQ.
  1. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288-300. [Crossref]  [PubMed] 
  2. Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med. 2014 Aug 6;7:203-215. [Crossref]  [PubMed]  [PMC] 
  3. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol. 2001;19(3):895-908. [Crossref]  [PubMed] 
  4. Lee S, Im SA, Kim GM, et al. Patient-reported outcomes of palbociclib plus exemestane with gnrh agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer: a prospective, open-label, randomized phase ll trial (KCSG-BR 15-10). Cancers (Basel). 2020;12(11):3265. [Crossref]  [PubMed]  [PMC] 
  5. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926-1936. [Crossref]  [PubMed] 
  6. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213. [Crossref]  [PubMed] 
  7. Ağargün MY, Kara H, Anlar O. Pittsburgh Uyku Kalitesi İndeksi'nin geçerliği ve güvenirliği [The validity and reliability of the Pittsburgh Sleep Quality Index]. Turk Psikiyatri Derg. 1996;7(2):107-115. [Link] 
  8. Mollayeva T, Thurairajah P, Burton K, Mollayeva S, Shapiro CM, Colantonio A. The Pittsburgh Sleep Quality Index as a screening tool for sleep dysfunction in clinical and non-clinical samples: a systematic review and meta-analysis. Sleep Med Rev. 2016 Feb;25:52-73. [Crossref]  [PubMed] 
  9. Robertson JF. Fulvestrant (Faslodex) -- how to make a good drug better. Oncologist. 2007;12(7):774-784. [Crossref]  [PubMed] 
  10. Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997-3005. [Crossref]  [PubMed] 
  11. Robertson JFR, Cheung KL, Noguchi S, et al. Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. Eur J Cancer. 2018 May;94:206-215. [Crossref]  [PubMed] 
  12. Kahan Z, Gil-Gil M, Ruiz-Borrego M, et al. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: patient-reported outcomes in the PEARL study. Eur J Cancer. 2021 Oct;156:70-82. [Crossref]  [PubMed] 
  13. Tripathy D, Curteis T, Hurvitz S, et al. Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer. Ther Adv Med Oncol. 2022 Feb 28;14:17588359221081203. [Crossref]  [PubMed]  [PMC] 
  14. Coates AS, Hürny C, Peterson HF, et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol. 2000;18(22):3768-3774. [Crossref]  [PubMed] 
  15. Besedovsky L, Lange T, Born J. Sleep and immune function. Pflugers Arch. 2012;463(1):121-137. [Crossref]  [PubMed]  [PMC] 
  16. Blask DE. Melatonin, sleep disturbance and cancer risk. Sleep Med Rev. 2009;13(4):257-264. [Crossref]  [PubMed]